We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+5.11%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.64B
AUM Growth
+$64M
Cap. Flow
-$23.9M
Cap. Flow %
-0.91%
Top 10 Hldgs %
39.72%
Holding
198
New
11
Increased
45
Reduced
37
Closed
18

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$17.5M
2
SYK icon
Stryker
SYK
+$12.2M
3
AZN icon
AstraZeneca
AZN
+$12.1M
4
DHR icon
Danaher
DHR
+$11.9M
5
PFE icon
Pfizer
PFE
+$11.1M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$13.6M
2
SHPG
Shire pic
SHPG
+$12.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$12.3M
4
ABT icon
Abbott
ABT
+$10.4M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$8.69M

Sector Composition

Rank Sector Weight
1 Healthcare 94.11%
2 Real Estate 3%
3 Miscellaneous 2.21%
4 Financials 0.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QHC
176
DELISTED
Quorum Health Corporation
QHC
$119K ﹤0.01%
23,725
– –
JNCE
177
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$78K ﹤0.01%
10,127
– –
CLDX icon
178
Celldex Therapeutics
CLDX
$3.05B
$53K ﹤0.01%
7,053
– –
CTMX icon
179
CytomX Therapeutics
CTMX
$617M
– –
-265,045
Closed -$7.54M
CYTK icon
180
Cytokinetics
CYTK
$9.76B
– –
-137,797
Closed -$992K
GKOS icon
181
Glaukos
GKOS
$9.79B
– –
-55,079
Closed -$1.7M
LXRX icon
182
Lexicon Pharmaceuticals
LXRX
$894M
– –
-231,054
Closed -$1.98M
NTRA icon
183
Natera
NTRA
$50.4B
– –
-103,731
Closed -$962K
PHG icon
184
Philips
PHG
$24.4B
– –
-99,248
Closed -$2.89M
PTCT icon
185
PTC Therapeutics
PTCT
$5.63B
– –
-24,299
Closed -$658K
XNCR icon
186
Xencor
XNCR
$1.78B
– –
-20,000
Closed -$600K
EIGR
187
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,528
Closed -$452K
MYOV
188
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-150,471
Closed -$3.2M
ABMD
189
DELISTED
Abiomed Inc
ABMD
– –
-6,514
Closed -$1.9M
QTNT
190
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-11,062
Closed -$2.08M
NTUS
191
DELISTED
Natus Medical Inc
NTUS
– –
-11,335
Closed -$381K
ADMS
192
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-16,699
Closed -$399K
ALDR
193
DELISTED
Alder Biopharmaceuticals
ALDR
– –
-279,950
Closed -$3.56M
FMI
194
DELISTED
Foundation Medicine, Inc.
FMI
– –
-6,353
Closed -$500K
AVXS
195
DELISTED
AveXis, Inc. Common Stock
AVXS
– –
-70,347
Closed -$8.69M
BHVN
196
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-162,477
Closed -$4.18M
4 5 6 7
8

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q2 2018 Portfolio in Review

As of Q2 2018, Tekla Capital Management held 198 positions worth $2.64B, up 2.5% from $2.57B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management's Q2 2018 filing shows 11 new, 45 increased, 37 reduced and 18 closed positions. Its largest new stake was Whitehawk Therapeutics: 51,000 shares worth $3.17M. The largest sale was Sarepta Therapeutics, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Real Estate and Miscellaneous.

  • Tekla Capital Management's largest Q2 2018 buy was Whitehawk Therapeutics: 51,000 shares worth $3.17M.
  • Tekla Capital Management added most to UnitedHealth in Q2 2018, an estimated $17.5M increase.
  • Tekla Capital Management's biggest Q2 2018 reduction was Sarepta Therapeutics, cutting an estimated $13.6M.
  • Tekla Capital Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $8.69M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.64B portfolio in Q2 2018.
  • Tekla Capital Management opened 11 new positions and closed 18 in Q2 2018.
  • Tekla Capital Management's portfolio value rose 2.5% quarter-over-quarter to $2.64B.

Based on Tekla Capital Management's 13F filing for Q2 2018, filed 13 Aug 2018.